METEOR Trial

Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis

N=984; patients with either age (mean 57 years) as the only coronary heart disease risk factor or 10-year FRS<10% and modest CIMT thickness (1.2 to <3.5 mm).

Patients were randomized to receive either 40 mg rosuvastatin or placebo.

In middle-aged adults with an FRS<10% and evidence of subclinical atherosclerosis, rosuvastatin resulted in statistically significant reduction in rate of progression of maximum CIMT over 2 years vs. placebo.